FDA approves niraparib for HRD-positive advanced ovarian cancer

MLA

“FDA Approves Niraparib for HRD-Positive Advanced Ovarian Cancer.” The Fly, Oct. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.603537070&authtype=sso&custid=ns315887.

APA

FDA approves niraparib for HRD-positive advanced ovarian cancer. (2019, October 23). The Fly.

Chicago

The Fly. 2019. “FDA Approves Niraparib for HRD-Positive Advanced Ovarian Cancer,” October 23. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.603537070&authtype=sso&custid=ns315887.